← boardnext 2028-02
TNXP
Tonix Pharmaceuticals, Inc.distress 7/10 · high distress / dilution risk$10.67+1%today-83% from 52w high
Lead: major depressive disorder · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$185M
Runway
1.5 yrs
Shares 1y
+82%
Price & events
-43.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.8%
1D
-10.0%
1W
-10.8%
1M
-14.6%
3M
-41.8%
6M
-76.6%
1Y
-81.3%
2Y
-100.0%
5Y
-100.0%
All
Overview
- Market Cap
- $170.09M
- Enterprise Value
- $-10.71M
- Volume
- 50.41K
- 52 Week Range
- $10.59 – $61.57
- Total Shares
- 15.94M
- Float Shares
- 15.01M
- Short %
- 22.50%
- % Held by Insiders
- 0.14%
- % Held by Institutions
- 45.79%
- RVOL
- 0.09x
- Beta
- 1.65
Pipeline stages · 2 programs
TNX-102 SL
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
TNX-1300 (Injection), Placebo (Injection)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-02 Estimated 50% readout ~2028-03-17 | Phase 2 | TNX-102 SLorphanrare pediatric | Major Depressive Episode (MDE), Major Depressive Disorder (MDD), Depression | — | recruiting |
| 2026-02-10 | Phase 1 | TNX-102 SL Tabletorphanrare pediatric | Pharmakokinetic, Open Label, Phase 1 | 50 | active not recruiting |
| 2025-04-21 | Phase 2 | TNX-1300 (Injection), Placebo (Injection) | Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse, Cocaine Adverse Reaction | 3 | terminated |
Catalyst news & presentations · 13
- in 2027trial initiationsecondaryPhase 2/3TNX-4800 · Initiate adaptive Phase 2/3 study of TNX-4800 for seasonal prevention of Lyme diseaseSEC 8-K
- first half of 2027Guided 55%trial initiationsecondaryPhase 2TNX-4800 · Proposed adaptive Phase 2 field study pending FDA agreementSEC 8-K
- 2nd half of 2026Guided 55%trial initiationsecondaryPhase 2TNX-1500 · Investigator-initiated study at Massachusetts General Hospital pending FDA clearance of IND.SEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- June 29, 2026trial initiationsecondaryPhase 2TNX-102 SL · First patient enrolled in HORIZON Phase 2 study of TNX-102 SL 5.6 mg as first-line monotherapy in adults with MDD.SEC 8-K
- 2026-06-01partnershipTONMYA · GPO agreement providing coverage for TONMYA to approximately 17 million additional U.S. commercial lives, effective June 1, 2026.SEC 8-K
- March 30, 2026conferencedata presentationsecondaryPhase 1TNX-4800 · Phase 1 data presented at World Vaccine Congress Washington 2026SEC 8-K
- March 26, 2026trial initiationsecondaryPhase 1TNX-1900 · First participant dosed in Phase 1 study to evaluate TNX-1900 effect on trigeminal nerve-mediated vasodilation using capsaicin and electrical stimulation.SEC 8-K
- shortly after Q4 2025trial initiationsecondaryPhase 2TNX-102 SL · Phase 2 clinical trials expected to start shortly after IND filingSEC 8-K
- fourth quarter of 2025regulatory submissionFiled (NDA/BLA)TNX-102 SL · IND filing planned for TNX-102 SL to expand indication to MDDSEC 8-K
- 2025-12-16partnershipTNX-4900 · Licensed exclusive worldwide rights from Rutgers University for chronic neuropathic pain.SEC 8-K
- 2025-09-29fda agreementTNX-2900 · FDA cleared IND for TNX-2900 to progress into Phase 2 development.SEC 8-K
- 2025-09-17partnershipTNX-4800 · In-licensed worldwide rights from UMass Chan Medical School for a Phase 2/3-ready monoclonal antibody targeting OspA of Borrelia burgdorferi for Lyme disease prevention.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $42 (+296% upside) · 5 analysts
- 2026-06-25Raymond JamesStrong Buy
- 2026-05-04TD CowenBuy
- 2025-03-20Noble Capital MarketsOutperform
- 2024-07-22Alliance Global PartnersBuy
Competitors — major depressive disorder
- NBIXNEUROCRINE BIOSCIENCES INC$17.2B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- XENEXenon Pharmaceuticals Inc.$6.3B · D3
- DFTXDefinium Therapeutics, Inc.$4.7B · D3
- SUPNSUPERNUS PHARMACEUTICALS, INC.$2.7B · D0
- BHVNBiohaven Ltd.$2.2B · D6
- SPTXSeaport Therapeutics, Inc.$1.2B · D1
- ANROAlto Neuroscience, Inc.$937M · D3
- NMRANeumora Therapeutics, Inc.$281M · D5
- HELPCYBIN INC.$175M · D5
Recent news
- 2026-07-21Total debt per share of Tonix Pharmaceuticals Holding Corp. – GETTEX:TPM0 - TradingView
- 2026-07-20Tonix shares TNX-4800 Lyme disease prevention presentation - Bitget
- 2026-07-20Tonix Pharmaceuticals publishes investor deck highlighting TONMYA fibromyalgia launch strategy - Bitget
- 2026-07-17Tonix Pharmaceuticals (TNXP) Investor presentation Summary - Quartr
- 2026-07-15Tonix Paper Introduces Three New Mouse Models for Mpox Vaccine Research - Stock Titan
- 2026-07-15Tonix Pharmaceuticals Announces Publication in the - GlobeNewswire
- 2026-07-14Precision Trading with Tonix Pharmaceuticals Holding Corp. (TNXP) Risk Zones - Stock Traders Daily
- 2026-07-13Tonix Pharmaceuticals (TNXP) Secures Medicare Coverage for Tonmy - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.